nesiritide, Sildenafil

Phase 1Small molecule

nesiritide, Sildenafil is one of 50 small molecule programs targeting Congestive Heart Failure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congestive Heart FailureActive, not recruiting

Congestive Heart FailurePhase 1

Active, not recruiting

Competition

Competitive Landscape

113 competitors in Congestive Heart Failure

#DrugCompanyPhaseTrials

Multaq

Sanofi

Phase 3

1 2

Actos

Takeda

Phase 3

1 3

Diabeta

Pfizer

Phase 3

1 4

Samsca

Otsuka

Phase 3

7 5

Natrecor

SScios, Inc.

Phase 3

6 6

Atacand

Coreg

1 8

Protonix

WWyeth-Lederle Vaccines

Phase 3

1 9

Injectafer

AAmerican Regent, Inc.

Phase 3

1 10

Feosol

AAuerbach Hematology Oncology Associates P C

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Congestive Heart Failure1 trial

Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

Terminated·MMayo Clinic·Phase 1·NCT00818701·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nesiritide, Sildenafil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nesiritide, Sildenafil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nesiritide, Sildenafil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMayo Clinic

nesiritide, Sildenafil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Congestive Heart Failure1 trial

References

Drug Info

Quick Facts

Related News